NCR1 and acute myeloid leukemia: As already described for other target antigens and cancers29, a bifunctional NKp46-NKCE targeting CD123 (NKp46-Fc null-CD123) had strong antitumor effects against the MOLM-13 AML cell line in vitro (Fig. 2b).